A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.

@article{Wiley2016ACD,
  title={A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.},
  author={Henry E. Wiley and Darby Thompson and Clare C Bailey and Emily Y. Chew and Catherine A. Cukras and Glenn J. Jaffe and Richard Wayne Lee and Erin K Loken and Catherine B. Meyerle and Wai T. Wong and Frederick L. Ferris},
  journal={Ophthalmology},
  year={2016},
  volume={123 4},
  pages={
          841-9
        }
}
PURPOSE To investigate the comparative efficacy of bevacizumab (Avastin) and ranibizumab (Lucentis; both Genentech, Inc, South San Francisco, CA) for diabetic macular edema (DME) using a crossover study design. DESIGN Randomized, double-masked, 36-week, 3-period crossover clinical trial. PARTICIPANTS Fifty-six subjects with DME involving the center of the macula in one or both eyes. METHODS Monthly intravitreous injections of bevacizumab (1.25 mg) or ranibizumab (0.3 mg). MAIN OUTCOME… CONTINUE READING
BETA
8
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Similar Papers

Loading similar papers…